Linker Ralf A, Chan Andrew
Department of Neurology, University of Regensburg, Universitätsstr. 84, 93053 Regensburg, Germany.
Ambulantes Neurozentrum, Inselspital, Bern University Hospital, Freiburgstr. 4, 3010 Bern, Switzerland.
Neurol Res Pract. 2019 Feb 28;1:5. doi: 10.1186/s42466-019-0005-5. eCollection 2019.
With the advent of modern immunotherapies for relapsing-remitting multiple sclerosis (RRMS) and the increasing amount of treatment options on the market, MS has evolved as a treatable disease. Yet, at the same time, new challenges for the treating neurologists arise.
This review article covers some of these challenges, including when and how to start treatment, treatment monitoring, and finally considerations on what the increasing choice in treatment options brings to disease management and longer-term planning. Among others, these important issues comprise pregnancy, treatment sequencing, switching or even stopping treatment.
The ultimate goal for navigating choices in RRMS management is to choose the right drug for the right patient at the right time Throughout the article, there is a strong focus on practical aspects and individual decision making in MS to meet the concept of personalized medicine.
随着用于复发缓解型多发性硬化症（RRMS）的现代免疫疗法的出现以及市场上治疗选择的不断增加，多发性硬化症已发展成为一种可治疗的疾病。然而，与此同时，治疗神经科医生也面临着新的挑战。
这篇综述文章涵盖了其中一些挑战，包括何时以及如何开始治疗、治疗监测，最后是关于治疗选择的增加给疾病管理和长期规划带来了什么的考量。其中，这些重要问题包括妊娠、治疗顺序、换药甚至停药。
在RRMS管理中做出选择的最终目标是在正确的时间为正确的患者选择正确的药物。在整篇文章中，重点强烈放在多发性硬化症的实际方面和个体决策上，以符合个性化医疗的概念。
